منابع پایان نامه درمورد دانشگاه علوم پزشکی، علوم پزشکی، خدمات بهداشتی، بیماران مبتلا

دانلود پایان نامه ارشد

77. Yoshinouchi M, Bongo A, Nakamura K, Kodama J, Itoh S, Sakai H, and Ludo T. Analysis by Multiplex PCR of the Physical Status of Human Papillomavirus Type 16 DNA in Cervical Cancers. J Clin Microbio11999; 37(11): 3514-3517.
78. Smotkin D, Wettstein EQ. Transcription of human papillomavirus type 16 early genes in a cervicalcancer and a cancer — derived cell line and identification of the E7 protein. Proc Natl Acad Sci USA 1986; 83: 4680-4684.
79. Motoyama S, Ladines-Llave CA, Vilanueva SL, and Marna T. The role of human papillomavirus in the molecular biology of cervical carcinogenesis. Kobe J Med Sci 2004; 50(1): 9-19.
80. Pornthanakasem W, Shotelersuk K, Termrungruanglert W, Voravud N, Niruthisard S, Mutirangura A. Human papillomavirus DNA in plasma of patients with cervical cancer. BMC Cancer. 2001; 1:2.
81. Jeon S, and Lambert PF. Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci 1995; 92: 1654-1658.
82. Durst M, Croce CM, Gissmann L, Schwarz E, and Huebner K. Papillomavirus sequences integrate near cellular oncogenes in some cervical carcinomas. Proc Natl Acad Sci 1987; 84: 1070-1074.
83. Wentzensen N, Vinolcurova S, and Doeberitz MK. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract .Cancer Res 2004; 64:3878-3884.
84. Hausen HZ. Human papillomaviruses in the pathogenesis of anogenital cancer. Virol 1991; 184: 9- 13
85.Mackova J, Kuttnova L, Hainz P, Krystofova J, Sroiler V, Otahal P, Gabriel P, and Nemeckova S. Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV16-E7 is inhibited by co-expression of 11,12. Int J Oncol 2004; 24: 1581-1588.

86.Rapp L, Chen JJ. The papillomavirus E6 proteins. Biochim Biophys Acta 1998; 1378: F1-F19Sons Ltd; 2000.2006Jul 18;103(29):10834-9.
87. Herber R, Liem A, Pitot H, and Lambert PF. Squamous epithelial hyperplasia and carcinoma in mice transgenic for the human papillomavirus type 16 E7 oncogene. J Viral 1996; 70(3): 1873-1881.
88.Sathish N, Abrahama P, Peedicayil A, Sridharan G, John S, Shaji RV, Chandye G. HPV DNA in plasma of patients with cervical carcinoma. J Clin Virol 2004; 31: 204-209.
89. Nathanson N. Viral Pathoaensis and Immunity; Liippincott Williams & Wilkins; 2″ edition. 2001.
90. Berezutskaya E. Bagshi S. The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome. J Biol Chem 1997; 272(48): 30135-30140.
91. Jei,vers RJ, Hildebrandt P, Ludlow JW, Kell B, and IvIcCance DJ. Regions of human papillomavirus type 16 E7 oncoprotein required for immortalization of human keratinocytes. J Virol 1992; 66(3): 1329-1335.
92. Barbosa MS, Edmonds C, Fisher C, Schiller J, Lowy D, and Vousden K. The region of the HPV E7 oncoprotein homologous to adenovirus E 1 a and SV40 large T antigens contains separate domains for Rb binding and casein kinase 11 pbosphorylation. EMBOJ 1990; 9(1): 153-160.
93. Pahel G, Aulabaugh A, Short SA, Barnes JA, Painter CR, Ray P, Phelps WC. Structural and functional characterization of the HPV16 E7 protein expressed in bacteria. I Biol Chem 1993; 268(34): 26018-26025.
94. JSchnning BH, Bevort M, Mikkelsen S, Andresen M, Thomsen P. Leffers H, Norrild B. Human papillomavirus type 16 E7-regulated genes: regulation of SlOOP and ADP/ATP carrier protein genes identified by differential-display technology. J Gen Viral 2000; 81: 1009-1015.
95. Song S, Gulliver GA, and Lambert PP. Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53- independent pathways. Proc Natl Acad Sci USA 1998; 95: 2290-2295.
96. Patel D, Incassati A, Wang N, and McCance DJ. Human papillomavirus type 16 E6 and E7 cause polypioidy in human keratinocytes and up-regulation of G2-M-phase proteins. Cancer Res 2004; 64: 1299-1306.
97. Gonzalez SL, Stremlau NI, He X, Basile JR, and Munger K. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J Virol 2001; 75(16): 7583-7591.
98. Schilling B, De-Medina T. Syken J, Vidal M, Munger K. A novel human Dna.I. protein, hTid-I, a homolog of the drosophila tumor suppressor protein Tid56, can interact with the human papillomavirus type 16 E7 oncoprotein. Viral 1998; 247: 74-85.
99. Lin KY, Guarnieri FJ, Staveley-O’Carroll KF, Levitsky HI, August ST, Pardoll DM, Wu TC. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996; 56: 21-26.
100. Gostout BS, Zanetta GM, Maleemonkol S, Kamat MR, McGovern RM, and Persing DH.Differential Distribution of sequence variation in HPV16 E6. Gynecol Oncol 2000; 79: 11-17.
101. Hu J. Han R, Cladel NM, Pickel MD, and Christensen ND. Intracutaneous DNA vaccination with the E8 gene of cottontail rabbit papillomavirus induces protective immunity against virus challenge in rabbits. J Virol 2002; 76(13): 6453-6459.
102. Szoke K, Sapy T, Krasznai Z, liernadi Z, Szladek G, Veress G, Dillner 3, Gergely L, and Konya J.Moderate variation of the oncogenic potential among high-risk human papillomavirus types in gynecologic patients with cervical abnormalities. 3 Med Virol 2003; 71: 585-592.
103. Laconi S, Greco M, Pellegrini-Bettoli P, Rais M, Laconi E, and Pani P. One-step detection and genotyping of human papillomavirus in cervical samples by reverse hybridization. Diag Mol Pathol 2001; 10(3): 200-206.
104.Thompson HSG, Davies ML, Holding FP, Fallon RE, Mann AE, Oneill T, and Roberts JSC. Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine 1999; 17: 40-49.
105. Kisseljov FL. Virus-Associated Human Tumors: Cervical Carcinomas and Papilloma Viruses.Biochem 2000; 65(I): 68-77.
106. Song S, Pitot PC, and Lambert PP. The human papillomavirus type 16 E6 gene alone is sufficient to induce carcinomas in transgenic animals. J Virol 1999; 73(7): 5887-5893.
107. Reeves WC, Gary HE, Johnson PT, IcenogIc JP, Brenes MM, Britton RM, Dobbins JG, and Schmid DS. Risk factors for genital papillomavirus infection in population at high and loW risk for cervical cancer. J Infect Dis 1994; 170: 753-758.
108. Inoue H, kondoh G, Kamakura CR, Yutsudo M, and Hakura A. Progression of rat embryo cells immortalized with transforming genes of human papillomavirus type 16. Virol 1991; 180: 191-198.
109. Lowy DR, and Schiller JT. Papillomavinises: prophylactic vaccine prospects. Biochimica et Biophysica Acta i 998; 1423: MI-M8.
110. Wakabayashi MT, Da Silva DM, Potkul RK. Comparison of human papillomavirus type 16 LI chimeric virus-like particles versus LI/L2 chimeric virus-like particles in tumor prevention. Intervirol 2002; 45: 300-307.
111. Thomas-Tikhonenko A, and Hunter CA. Infection and cancer: the common vein. Cytokine & Growth Factor Rev 2003; 14: 67-77.
112. Ho L, Terry G, Londesborough P, Cuzick J, Lorenzato F, and Singer A. Human papillomavirus DNA detection in the management of women with twice mildly abnormal cytological smears. J Med Virol 2003; 69: 118-121.
113. Pagliusi SR, Aguado MT. Efficacy and other milestones for human papillomaviruS vaccine introduction. Vaccine 2004; 23: 569-578.
114. Nakagawa M, Kim KH, and Moscicki AB. Different methods of identifying new antigenic epitopes of human papillomavirus type 16 E6 and E7 proteins. Clin Diagn Lab Immunol 2004; 11(5): 889-896.
115. Frazer LH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004; 4: 46-54
116. Roden RBS, Ling M, and Wu TC. Vaccination to prevent and treat cervical cancer. J Hum Path 2004; 35 (8): 971-982.
117. Oha YK., Sohna T, Parkb JS, Kangb MJ, Choic HG, Kimc JA, Kimd WK, Koa JJ, Kimb CK.Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant. V irol 2004; 328: 266-273.
118. Flint Si, Enquist LW, Racanillo VR, Sakalka AM. Principle of Virology. ASM press. 2nd; 2004.
119. Ngelangel C, Munoz N, Bosch FX, Limson GM, Festin MR, Deacon J, Jacobs MV, santamaria M, Maijer CJLM, and Walboomers JMM. Causes of cervical cancer in the Philippines: a case-control study. J Natl Cancer Inst 1998; 90: 43-49.
120. Brinkman JA, Jones WE, Gaffga AM, Sanders JA, Chaturvedi AK, Slavinsky m J, Clayton JL, Dumestre J, and Hagensee ME. Detection of Human Papillomavirus DNA in Urine Specimens from Human Immunodeficiency Virus-Positive Women. I Clin Microbial 2002; 40(9): 3155-3161.
121. Arbeit JM, Howley PM, and Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Nati Acad Sci USA 1996; 93: 2930-2935.
.122 گل محمدلو سریه. بررسی بیماران مبتلا به سرطان دهانه رحم از نظر تشخیص و درمان طی سه سال گذشته در بیمارستان زنان و مامایی تبریز پایان نامه جهت دریافت درجه تخصص در رشته زنان و زایمان دانشگاه علوم پزشکی تبریز . دانشکده پزشکی
.123 سالنامه آماری مرکز ایران. سازمان برنامه و بودجه مرکز آمار ایران.1374.502-498
124. عطاری پور شیوا ، طالبی اردشیر . بررسی فراوانی تغییرات بدخیم و پیش بدخیم در 4600 پاپ اسمیر اصفهان. دانشگاه علوم پزشکی و خدمات بهداشتی درمانی شهید صدوقی یزد.1378. مجله سال 7 ش40.1-44
125.Hamkar R, Mokhtari-Azad T, and et al, Prevalence of varies types of human papillomaviruses among cervical cancer and normal biopsy specimens in the Mazandaran province in Iran. East Mediter Health J 2002; 8(6): 805-811.
126. Hamknr R, Molchtari-Azad T, and et al, Determination of human papillomavirus genotypes among normal and cancerous biopsy specimens in North of Iran. Iranian J Infect Dis Tropic Med 2004; 8(22): 9.
127. Farjadian S, Asadi E, Doroudchi M,

پایان نامه
Previous Entries منبع مقاله درباره استان خراسان، کشورهای در حال توسعه، سازمان بهداشت جهانی، ابتلا به بیماری Next Entries منابع پایان نامه درمورد and، of، cervical، the